

REGISTER BEFORE OCTOBER 19
& SAVE UP TO \$750

November 13-15 | Boston

www.complement-therapeutics.com

2nd Annual
**Complement-based
Drug Development**
Summit 2018



**Optimize Complex Discovery,
Biomarker Validation &
Clinical Translation to Develop
Complement Inhibition for Rare
& Common Diseases**

Expert Speakers Including:



Mark Ma
Senior Director Bioanalytical
and Biomarker Development
Alexion Research



Simon Read
Chief Scientific Officer
Ra Pharma



Niels Riedemann
Chief Executive Officer
InflaRx



Adam Rogers
Chief Executive Officer
Hemera Biosciences



Frank Baas
Chief Scientific Officer
Complement Pharma



Lukas Scheibler
Executive Vice
President Research and
Translational Medicine
Apellis Pharmaceuticals



Mingjun Huang
Senior Vice President
Achillion Pharmaceuticals



Michael McCaleb
Vice President of Clinical
Development
Ionis Pharmaceuticals



Mel Berger
Senior Medical Director,
Immunology R&D
CSL Behring

EXPERTISE PARTNER



HOSTING PARTNER



EXHIBITOR



Welcome to the 2nd Annual Complement-based Drug Development Summit

Seize the therapeutic opportunity of complement inhibition, in rare and common disease indications.

Since the first approval of Soliris over a decade ago, there is a huge opportunity in the industry to focus on the effects of the complement system outside of C5 and ultra-rare diseases.

The 2nd Complement Summit will capture this excitement by exploring the growing expansion of druggable targets in the complement system and identify which disease indications can benefit most.

Do not miss your chance to **network with the industry leaders** as they explore the most up-to-date **clinical advances**, methods to identify **key markers of efficacy** and strategies to **optimize translatable assays** to allow for clinical comparisons.

Hear What Previous Attendees Have To Say

Great conference. Very organized and well run. A great range of presentation topics and very informative

The Atypical HUS Foundation

There was a well-balanced mix of speakers representing early and late drug development efforts and approaches that have worked and ones that have failed. We often only hear the success stories, but one can learn maybe even more from the failures

Ablynx

What Can You Expect?



150+
Attendees



8+
Hours of Dedicated
Networking



18
World Class
Speakers



12+
Case Studies

Join Industry Thought Leaders as They Discuss The Key Challenges Limiting This Field:

1.

Create Translatable Complement Assays

Explore the need for a standardized assay to minimize variation between labs and accurately determine clear and reliable clinical comparisons.



2.

Identify which Common Indication will Benefit Most

As the industry delves into targeting common disease indications, this meeting will explore which indication has the most potential for clinical success.



3.

Identify Novel Biomarkers to Improve Efficacy Assessments

Identify biomarkers that are driving disease and indicating complement activation to allow accurate measurements of efficacy and endpoints.



4.

The Value of Animal Models to Predict Translation

Explore the validity of animal models in complement therapeutics and their relevance in human translation to improve preclinical conclusions.



5.

The Role of Complement in the CNS

Understand the biology of complement in the CNS and explore which complexes can be targeted to treat neurological disorders.



WHAT'S NEW FOR 2018?

Returning for the 2nd time, the **Complement-based Drug Development Summit** is back and better than ever! Explore the role of complement in rare and more common disease indications as the field uncovers which indication is best to target next. Here is a selection of the new content for this year:

NEW



The Role of Complement in the CNS

This year **Complement Pharma** will be divulging in their preclinical updates exploring the role of MAC in neurological disorders. Join the discussion with **Dimitrios Kapogiannis, NINDS**, as he explores the biology of complement in Alzheimer's disease outlining which biomarkers can be used to address patient selection and clinical outcomes.

NEW



Clinical Targeting of Complement in Common Disease Indications

There is huge opportunity in the industry to focus on the effects of the complement system outside of ultra-rare diseases, so this year we are highlighting the clinical developments of complement inhibition in: **solid-organ transplantation, neurological disorders, inflammatory diseases** and **age-related macular degeneration**.

NEW



Safety Risks Associated with Complement Inhibition

As more complement trials move into late stage clinical development, it is important to acknowledge the safety risks associated with complement inhibition. Join the in-depth discussion session exploring the safety risks of Meningococcal disease as a result of complement inhibition.

HIGHLIGHT

Opportunities to Collaborate

More than 6 hours have been dedicated to creating a forum for attendees to network and share ideas, whether in an audience discussion or networking reception.

HIGHLIGHT

Speed Networking

Get stuck into our networking sessions and exchange introductions with senior experts in the complement space whilst identifying yourself as a key thought leader.

HIGHLIGHT

Take Away Industry Lessons Learned

With the clinical landscape of the complement industry being explored, take away lessons-learned from industry leaders to ensure your pipeline has clinical success.

“This conference was one of the most organized conferences that I have ever attended. I have been in the business for 32 years. I know the difference... Thank you all for this great, productive, informative and fun event”

Past Attendee, Quidel

Expert Speakers



Mark Ma
Senior Director,
Bioanalytical
and Biomarker
Development
Alexion Research



Mingjun Huang
Senior Vice President
& Head of Research
**Achillion
Pharmaceuticals**



Anna Borodovsky
Principal Scientist
Alnylam Inc



Lukas Scheibler
Executive Vice
President, Research
and Translatable
Medicine
**Apellis
Pharmaceuticals**



Rajinder Singh
Senior Vice President
of Research
ChemoCentryx



Mel Berger
Senior Medical
Director,
Immunology R&D
CSL Behring



Frank Baas
Chief Scientific
Officer
**Complement
Pharma**



Sharookh Kapadia
Sr. Scientist and
Project Team Leader,
Infectious Diseases
Genentech



Adam Rogers
Chief Executive
Officer
Hemera Biosciences



Niels Riedemann
Chief Executive
Officer
InflaRx



Michael McCaleb
Vice President,
Clinical
Development
**Ionis
Pharmaceuticals**



Mike Ero
Chief Executive
Officer
**Machao
Diagnostics**



Andrew Luster
Chief, Division of
Rheumatology,
Allergy and
Immunology &
Director, Center
for Immunology
and Inflammatory
Diseases
**Massachusetts
General Hospital**



**Dimitrios
Kapogiannis**
Clinical Investigator
**National Institute
of Neurological
Disorders and
Stroke**



Simon Read
Chief Scientific
Officer
Ra Pharma



**Barbara
Klughammer**
Senior Principal
Scientist
**Roche Pharma
Research and Early
Development**



Dan Granoff
Clarox Endowed
Chair and Director,
Center for
Immunobiology
and Vaccine
Development
**UCSF Benioff
Children's Hospital
Oakland Research
Institute**



Sanjay Ram
Professor of
Medicine
**University of
Massachusetts
Medical School**

Conference Day One | Wednesday 14th November

8.00 Registration & Morning Refreshments

9.00 Chair's Opening Remarks

Explore Which Complement Target has the Most Clinical Success in Rare Disorders



Mingjun Huang
Senior Vice President
& Head of Research
**Achillion
Pharmaceuticals**

9.30 Discovery and Development of Oral Complement Factor D Inhibitors

- Rationales for discovery and development of small molecules targeting at complement factor D
- Preclinical assessments of complement factor D inhibitors
- Clinical assessments of complement factor D inhibitors



Simon Read
Chief Scientific
Officer
Ra Pharma

10.00 Developing a Pipeline of Complement Inhibitors; Lessons from Preclinical and Clinical Development

- Clinical Development of RA101495: Update on Phase 1 and phase 2 studies
- Developing a pipeline of macrocyclic Factor D inhibitors
- Leveraging macrocyclic peptides for small molecule discovery, with a focus on the identification of orally bioavailable 1st in class, small molecule inhibitors of Complement C5



Lukas Scheibler
Executive Vice
President Research
and Translational
Medicine
**Apellis
Pharmaceuticals**

10.30 C3 Inhibition with APL-2 in Rare Diseases

- An update on the clinical development of APL-2, a potent C3 inhibitor, will be provided
- 'Proof of Concept' has been demonstrated with APL-2 for the treatment of Paroxysmal nocturnal hemoglobinuria (PNH) and Geographic Atrophy (GA)
- APL-2 is developed in other indications such as complement dependent nephropathies, autoimmune hemolytic anemia among others

11.00 Morning Refreshments & Speed Networking

Improve Translational Biomarkers to Understand Complements' Involvement in Any Given Disease State



Mark Ma
Senior Director
Bioanalytical
and Biomarker
Development
Alexion Research

12.00 Bioanalytical Approaches in Supporting Rare Disease Therapeutics

- Introduction of rare disease
- Challenges in developing suitable bioanalytical strategy for support of rare disease R&D
- Alexion's experiences of bioanalytical innovation and quality enhancement



Mike Ero
Chief Executive
Officer
**Machaon
Diagnostics**

12.30 Significant Advances in Genetic Testing within Clinical Trials

- Presentation details to be confirmed

13.00 Lunch Time Refreshments



Barbara Klughammer
Senior Principal
Scientist
**Roche Pharma
Research and Early
Development**

14.00 Total C5 in PNH Patients Treated with SKY59/RO7112689

- Sequential Monoclonal Antibody Recycling Technology (SMART)
- Total C5 accumulation during treatment with C5 targeting antibodies



Simon Read
Chief Scientific
Officer
Ra Pharma



Mark Ma
Senior Director
Bioanalytical
and Biomarker
Development
Alexion Research

14.30 Panel Discussion: The Role of Translational Biomarker Activities in the Development of Complement Therapeutics

- Identify the current signatures that suggest complement is the primary driver of disease
- Review current procedures of assay standardization and their deficiencies
- Explore the next generation of translatable and standardized complement assays to allow for clinical comparisons

15.30 Afternoon Refreshments

16.30 Round Table Discussion Session

1. Role of Complement in the CNS

- Where is complement found in the nervous system?
- Is complement a causal factor of the early onset of CNS diseases like Alzheimer's?
- What CNS disease would benefit most from a complement therapeutic?

2. The Value and Validity of Animal Models to Ensure Reliable Translation

- What are the restraints in reflecting the complement system in a mouse model?
- What are the potential pitfalls when working with animal models?
- What are the potential tests which could be carried out to address complement activation?

3. Which Indication has the Most Clinical Success?

- What are the most interesting emerging areas in this space that could have the greatest potential?
- What are the different hurdles that face common diseases vs rare diseases?

4. Next Generation of Translatable and Standardized Complement Assays

- What are the restraints of current complement reagents?
- How can the field move towards having a standardized complement assay?
- What parameters would a standardized complement assay consist of to ensure comparable and reliable data?



Dimitrios Kapogiannis
Clinical Investigator
**National Institute of
Neurological Disorders
and Stroke**



Anna Borodovsky
Principal Scientist
Alnylam Inc



Rajinder Singh
Senior Vice President of
Research
ChemoCentryx

17.30 Chair's Closing Remarks

17.35 End of Day One

📌 This summit provides a great opportunity to learn about new approaches for designing, manufacturing and developing treatments in this area. It's a great venue to meet peers, understand new and novel approaches in the space and identify new opportunities to further your research and development activities. Great meeting and looking forward to next year's conference 📌

Past CVI Summit Attendee, Pfizer

Conference Day Two | Thursday 15th November

8.00 Registration & Morning Refreshments

9.00 Chairman's Opening Remarks

Novel Approaches to Understand Complement in Physiology and Disease



Andrew Luster
Chief, Division of
Rheumatology,
Allergy and
Immunology &
Director, Center
for Immunology
and Inflammatory
Diseases
**Massachusetts
General Hospital**

9.30 In Vivo Imaging of Arthritic Joints Reveals a New Function for an Old Mediator

- C5a and C5aR are required for immune-complex induced inflammatory arthritis
- C5a generated in the joint is transcytosed and presented on joint endothelium to blood borne leukocytes
- C5aR initiates neutrophil arrest on joint endothelium required for transendothelial migration and entry into the joint



Sharookh Kapadia
Sr. Scientist and
Project Team Leader,
Infectious Diseases
Genentech

10.00 Inhibition of Essential Gram-negative Bacterial Membrane Biogenesis Pathways to Enhance Complement-mediated Clearance

- Bacteria have evolved multiple mechanisms to resist immune recognition and killing in vivo, in particular against complement-mediated lysis and clearance
- Develop novel antibacterial therapies to treat unmet Gram-negative bacterial infections by targeting essential bacterial pathways that, when regulated, lead to enhanced immune-mediated clearance
- Determine if targeting specific essential outer membrane biogenesis pathways in bacteria leads to enhanced complement-dependent clearance

10.30 Morning Refreshments and Poster Session

Optimize Therapeutics with Pathway-Specific Targeting in Common Disease Indications



Mel Berger
Senior Medical
Director, Immunology
R&D
CSL Behring

11.30 Complement and C1 Inhibitor in Solid Organ Transplantation

- Complement plays important roles in ischemia-reperfusion injury-delayed graft function and in antibody-mediated rejection of solid organ allografts
- Complement is also likely involved in increasing allo-sensitization/immunologic memory
- Clinical trial data suggests that C1-Inhibitor may be beneficial in ameliorating the adverse effects of complement activation in solid organ transplantation



Niels Riedemann
Chief Executive
Officer
InflaRx

12.00 Targeting C5a for Chronic and Autoimmune Inflammatory Diseases

- Explore the MoA of C5a and its potential as target in inflammatory diseases
- Discuss IFX-1, first-in-class anti-human C5a monoclonal antibody which is being developed in chronic inflammatory diseases
- Discuss ongoing clinical trials and reflect on progress in common indications



Adam Rogers
Chief Executive
Officer
Hemera Biosciences

12.30 HMR59 for the Treatment of Age-related Macular Degeneration

- Blocking complement at Membrane Attack Complex
- HMR-1001 6-month results for the treatment of dry AMD
- HMR-1002 for the treatment of wet AMD

12.50 Lunch & Networking

13.50 Panel Discussion: Identify Which Indication will Benefit Most from Complement Therapeutics to Maximize Clinical Efficacy

- What common disease indication has the most potential for clinical success?
- How much inhibition is necessary to control disease and reduce safety risks?
- Rationale behind which complement complex to target

14.50 Afternoon refreshments



Michael McCaleb
Vice President of
Clinical Development
**Ionis
Pharmaceuticals**

15.20 Complement Factor B Inhibitor, IONIS-FB-LRX, for Age-Related Macular Degeneration

- Explore the results of complement factor B inhibition in healthy volunteers
- Assess the results of FB antisense oligonucleotides (ASO) in various common disease indications
- Discuss the clinical analyses of complement in phase 1 studies



Frank Baas
Chief Scientific
Officer
**Complement
Pharma**

15.50 The Role of Complement, especially the Membrane Attack Complex, in Neurological Disorders

- MAC deposition in neurological disorders
- Development of MAC inhibitors
- The effect of inhibitors on the terminal pathway in preclinical models

16.20 Chairman's Closing Remarks

16.30 End of Day Two

“This meeting gave us the chance to understand a growing and important therapeutic field. It allowed us to make decisions that were a win-win for our organization and the patients”

Past CVI Summit Attendee, Roche
Diagnostics Group



PRE-CONFERENCE WORKSHOPS

Workshop Day | Tuesday 13th November

Workshop A

Explore the Safety Risks of Meningococcal Disease as a Result of Complement Inhibition

9:00 - 12:00

As more complement trials move into late stage clinical development, it is important to acknowledge and discuss the safety risks that are hindering complement therapeutics. This session will explore clinical data to address the risk of contracting meningococcal disease as a result of complement inhibition and ways to manage and mitigate this risk effectively.

Attendees will explore:

- Complement interactions with the pathogenic *Neisseriae*
- Invasive *Neisseria* infections in patients treated with eculizumab (Soliris®)
- Meningococcal vaccination in patients treated with therapeutic inhibitors of complement

Workshop Leaders



Dan Granoff

Clarox Endowed Chair
and Director, Center for
Immunobiology and Vaccine
Development

**UCSF Benioff Children's Hospital
Oakland Research Institute**



Sanjay Ram

Professor of Medicine
**University of Massachusetts
Medical School**

Workshop B

Circulating Extracellular Vesicles of Neuronal and Astrocytic Origin: Carriers of Complement Biomarkers and Effectors in Alzheimer's Disease Pathogenesis

13:00 - 16:00

The complement system has an important role in normal brain development however can also be implicated in neurological diseases following unanticipated activity, usually in the form of driving inflammation to exacerbate the disease. This workshop explores the roles of biomarkers in neurodegenerative diseases and gives a brief introduction to extracellular vesicle biogenesis, morphology and functional significance.

Attendees will learn:

- Methodology for isolating extracellular vesicles of neuronal and astrocytic origin from the circulation
- Current findings of biomarker discovery and validation studies for Alzheimer's disease, with emphasis in complement and inflammation
- How extracellular vesicle biomarkers can assist in therapeutic discovery for neurodegenerative diseases (patient selection, outcomes)
- Recent findings suggesting that circulating extracellular vesicles may have complement-mediated toxicity and play roles in the pathogenesis of Alzheimer's disease

Workshop Leader



Dimitrios Kapogiannis

Clinical Investigator
**National Institute of
Neurological Disorders and
Stroke**

SPONSOR



Expertise Partner

Machaon Diagnostics is a preferred laboratory partner to pharmaceutical firms conducting clinical trials in

the areas of thrombosis, hemostasis, nephrology and rare disease. We offer both CAP/CLIA and GLP testing and regulatory-compliant method validation solutions for submission to the FDA and other regulatory bodies. Machaon Diagnostics has emerged as a leading laboratory for complement gene sequencing and other testing, due to our rapid turnaround and expedited study capabilities. Machaon was founded in 2003.

www.MachaonDiagnostics.com



Hosting Partner

Bioverativ, a Sanofi company, is dedicated to transforming the lives of people with rare blood disorders. Our hemophilia

therapies when launched represented the first major advancements in hemophilia treatment in nearly two decades, and we are inspired to push scientific boundaries to make a meaningful impact in the lives of people with cold agglutinin disease, hemophilia, beta thalassemia, and sickle cell disease.

www.bioverativ.com

Are you front of mind when pharma and biotech look to develop commercially viable complement therapeutics?

Complement-based drug developers have informed us that one of the most pressing problems in this rapidly growing field is that service providers lack knowledge and experience of the industry, forcing developers to use time and resources on work that they would rather outsource.

This is the perfect opportunity to demonstrate that you have the desire and capability to meet the increasing demands of this emerging field, and cement your position as the industry leader.




Exhibitor

Products Group is focused on providing innovative research and diagnostic tools for identification of novel markers

in autoimmune and Complement. Many of these products are unique in nature and provide researchers and clinicians valuable scientific and diagnostic information. Quidel offers products to meet biosafety testing and Complement dependent cytotoxicity testing requirements, such as normal human sera, proteins, monoclonal and polyclonal antibodies, depleted sera and Complement fragment ELISA assays.


www.quidel.com/spg

LAST YEAR'S AUDIENCE COMPOSITION:



*Based on market research and previous events' statistics

SENIORITY OF ATTENDEES



*Based on market research and previous events' statistics

BECOME A PARTNER



Jonathan Kilby-Phillips

Commercial Director

T.+1 617 455 4188

E. Sponsor@hansonwade.com

www.complement-therapeutics.com

PRICING

Register

www.complement-therapeutics.com/register

Tel: +1 617 455 4188

Email: register@hansonwade.com

Mail:
Hanson Wade
4th Floor, 52 Grosvenor
Gardens,
London, SW1W 0AU

Team Discounts*

- **10% discount** – 3 delegates
- **15% discount** – 4 delegates
- **20% discount** – 5 or more delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Top 3 Benefits of Attending

- 1 Gain** a comprehensive understanding of what each key drug developer in this space is currently working on, and the most interesting avenues for advancement in the coming years.
- 2 Meet**, network and discuss the key challenges in complement therapeutics with the field's thought leaders during interactive roundtable sessions and panel discussions.
- 3 Join** senior level industry figures to analyze the most efficient changes that can be made to improve research, development and manufacturing of complement-based drugs.


STANDARD PRICING

	Register & pay before Friday October 19	Standard Pricing
Gold: Conference & 2 workshops	\$3597 (save \$500)	\$3797 (save \$300)
Silver: Conference & 1 workshop	\$3098 (save \$300)	\$3298 (save \$100)
Bronze: Conference only	\$2499 (save \$200)	\$2699
Workshops - individual	\$699	

INDUSTRY PRICING*

	Register & pay before Friday October 19	Standard Pricing
Gold: Conference & 2 workshops	\$2899 (save \$400)	\$3299 (save \$398)
Silver: Conference & 1 workshop	\$2499 (save \$300)	\$2799 (save \$200)
Bronze: Conference only	\$2099 (save \$200)	\$2299
Workshops - individual	\$699	

*Pharma and biotech companies currently and publically developing complement based drugs for therapeutic use.



VENUE

Hilton Boston Logan Airport
One Hotel Drive, Boston,
Massachusetts, 02128, USA

For further information or assistance, please visit
www.bostonlogan.hilton.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

Code: 8149